Professional-grade financial intelligence

20M+ securities. Real-time data. Institutional insights.

Subscribe for $2

Trusted by professionals at Goldman Sachs, BlackRock, and JPMorgan

Overview
Profile
Novavax Stock

Novavax Stock NVAX

NVAX
US6700024010
A2PKMZ

Price

0
Today +/-
-0
Today %
-0 %

Novavax stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Novavax stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Novavax stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Novavax stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Novavax's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Novavax Stock Price History

DateNovavax Price
7/16/20250 undefined
7/16/20256.78 undefined
7/15/20256.82 undefined
7/14/20256.96 undefined
7/11/20256.89 undefined
7/11/20256.89 undefined
7/10/20257.13 undefined
7/9/20257.04 undefined
7/8/20257.04 undefined
7/7/20256.61 undefined
7/3/20256.85 undefined
7/2/20256.80 undefined
7/1/20256.63 undefined
6/30/20256.37 undefined
6/27/20256.42 undefined
6/27/20256.40 undefined
6/26/20256.47 undefined
6/25/20256.45 undefined
6/24/20256.54 undefined
6/23/20256.35 undefined
6/20/20256.44 undefined
6/20/20256.43 undefined
6/18/20256.30 undefined
6/18/20256.30 undefined
6/17/20256.55 undefined
6/16/20257.04 undefined

Novavax Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Novavax, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Novavax from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Novavax’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Novavax. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Novavax’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Novavax’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Novavax’s growth potential.

Novavax Revenue, EBIT and net profit per share

DateNovavax RevenueNovavax EBITNovavax Net Income
2030e460.87 M undefined0 undefined83.83 M undefined
2029e402.87 M undefined139.2 M undefined68.3 M undefined
2028e406.3 M undefined151.95 M undefined110.22 M undefined
2027e277.23 M undefined3.29 M undefined-49.11 M undefined
2026e507.7 M undefined91.32 M undefined29.49 M undefined
2025e1.06 B undefined483.44 M undefined369.79 M undefined
2024682.16 M undefined-231.93 M undefined-187.5 M undefined
2023983.71 M undefined-552.21 M undefined-545.06 M undefined
20221.98 B undefined-644.7 M undefined-657.9 M undefined
20211.15 B undefined-1.69 B undefined-1.74 B undefined
2020475.6 M undefined-416.7 M undefined-418.3 M undefined
201918.7 M undefined-129.6 M undefined-132.7 M undefined
201834.3 M undefined-173.9 M undefined-184.7 M undefined
201731.2 M undefined-171.7 M undefined-183.8 M undefined
201615.4 M undefined-269.1 M undefined-280 M undefined
201536.3 M undefined-157.2 M undefined-156.9 M undefined
201430.7 M undefined-83.7 M undefined-82.9 M undefined
201320.9 M undefined-52.4 M undefined-52 M undefined
201222.1 M undefined-29.7 M undefined-28.5 M undefined
201114.7 M undefined-21.6 M undefined-19.4 M undefined
2010300,000 undefined-38.5 M undefined-35.7 M undefined
2009300,000 undefined-37.4 M undefined-40.3 M undefined
20081.1 M undefined-34.4 M undefined-34.5 M undefined
20071.5 M undefined-30.3 M undefined-34.8 M undefined
20061.7 M undefined-21.1 M undefined-23.1 M undefined
20055.3 M undefined-15.2 M undefined-11.2 M undefined

Novavax Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (B)
NET INCOME (M)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
19911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
00000000000.020.020.010.010.01000000.010.020.020.030.040.020.030.030.020.481.151.980.980.681.060.510.280.410.40.46
---------100.001,100.00-37.50-26.67-27.27-37.50-80.00-----57.14-9.0950.0020.00-58.33106.679.68-47.062,538.89141.2672.86-50.38-30.6255.43-52.17-45.3646.57-0.9914.43
-48,000.00------100.00100.0083.3373.3381.8250.0080.00100.0048,000.0048,000.00--50.0031.8260.0050.001,333.333,200.001,548.391,411.762,666.67101.0541.8854.4765.1170.3845.2894.67173.29118.23119.40104.35
00000000000.020.010.0100000000.010.010.010.0200000001.080.640.48000000
-2-2-4-5-8-5-4-7-4-12-9-22-17-25-11-23-34-34-40-35-19-28-52-82-156-280-183-184-132-418-1,743-657-545-18736929-491106883
--100.0025.0060.00-37.50-20.0075.00-42.86200.00-25.00144.44-22.7347.06-56.00109.0947.83-17.65-12.50-45.7147.3785.7157.6990.2479.49-34.640.55-28.26216.67316.99-62.31-17.05-65.69-297.33-92.14-268.97-324.49-38.1822.06
0.50.50.50.50.50.50.60.60.711.11.21.51.82.12.93.13.44.35.25.76.68.511.313.113.514.618.524.157.674.478.2100.77152.19000000
----------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Novavax Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Novavax is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (B)
RECEIVABLES (M)
OTHER REC. (k)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (B)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (M)
TOTAL ASSETS (B)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (B)
RETAINED EARNINGS (M)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (M)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (B)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (B)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (B)
DEBT (B)
TOTAL CAPITAL (B)
1994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                                             
0000000.010.0200.030.020.030.070.050.030.040.030.020.040.130.170.230.240.160.090.080.711.521.340.570.92
0.5000.30.10.313.91.920.83.60.50.70.30.30.13.82.66.910.62.30.2007.526245582.4297.240
0100000000300200200090080000000000000000000
0000000.50.50.60.93.50.80.10.30000000000000036.741.78.75
00.10.20.200.10.80.60.31.11.312.20.80.91.31.643.859.554.352.14627.210.9275.1185247.5236.4589
0000000.020.030.010.030.020.040.080.050.040.040.030.030.050.150.190.290.290.20.120.11.252.161.71.141.02
1.51.410.911.11.94.313.715.214.111.69.95.78.27.88.26.911.514.319.732.340.23628.417.9187.7268.8400.5490.99300
0000000000000000006.2000000000000
0000000000000000000000000000000
1.11.41.51.61.6004.643.351.1100000016.312.610.89.27.96.55.65.74.8000
000002.337.633.133.133.133.133.133.133.133.133.133.133.133.158.754.653.151.753.65251.2135.4131.5126.3127.45107
0000.100000.50.41.70.90.63.40.20.20.20.51.10.90.92.65.41.81.81.15.416.628.535.1620
2.62.82.52.62.63.439.54251.35253.946.744.642.241.541.141.540.551.990.287.898.8106.599.388.775.8334.2421.7555.3653.6427
00.010.010.01000.060.070.060.080.080.080.120.090.080.090.070.070.10.240.280.390.390.30.210.171.582.582.261.81.45
                                                             
00.10.10.10.10.20.20.20.30.30.40.50.60.60.711.11.21.52.12.42.72.73.23.80.30.70.80.91.411.62
00.030.030.040.040.050.090.10.10.140.170.20.260.260.280.350.370.380.440.610.730.950.941.021.141.262.543.353.744.194.5
-20-21.3-26.8-31.3-38.4-42.9-55.1-64.8-87.5-104.8-130.7-141.9-165-199.7-235.8-274.6-310.3-329.7-358.2-410.1-493.1-650-930-1,114.4-1,299.1-1,431.8-1,874.2-3,618-4,275.9-4,820.95-5,008
17.8-1.9-0.600000-1.5-1.5-1.5-1.9-10-1.6-0.8-0.80.80.40.8-6.6-9.1-11.8-8.6-11.2-12.57-1.4-6.42.72-23
0000000000000000000000000000000
-2.27.15.16.72.92.936.733.313.738.335.752.196.465.547.972.361.556.282.6205.7232.1295.2-3.1-99.3-165.5-183.4669-266.6-543.4-624.66-528.38
0.10.40.40.20.80.51.41.42.52.33.21.41.31.51.82.13.62.63.2612.911.95.75.69.32.954.3127.1216.5132.6142
0.100.2000.33.24.32.81.24.12.62.83.435.46.34.57.310.419.426.729.634.724.621.2146.3704.7608417.65221
0000000000000000000000.040.030.030.0100.271.431.281.080.89
0000000000000000000000000000000
000000000.21.11.20.70.71.122.40.10.100.210.60.40000105.9130.5352.15.147.01
00000000.010.0100.0100.010.010.030.010.010.010.010.020.030.080.070.070.050.030.582.392.461.641.16
000000203041.141.13629.722.521.60.50.40.30.311.20.40316.3317.8319.2320.6362.1323.5197.7223.94223
0000000000000000000000000000000
5.10000002.62.52.30.20.20.10.42.97.25.24.89.412.611.916.917.112.811.212.613.5214.6235.1655.34806
0.01000000.020.030.040.040.040.030.020.0200.010.010.010.010.010.010.020.330.330.330.330.380.540.430.881.03
0.01000000.020.040.050.050.040.030.030.030.030.020.020.010.020.030.050.090.40.40.380.360.962.932.892.512.18
00.010.010.01000.060.070.060.090.080.090.120.090.080.090.080.070.10.240.280.390.40.310.210.181.622.662.351.891.66
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Novavax provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Novavax's financial health and stability.

Assets

Novavax's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Novavax must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Novavax after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Novavax's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (B)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (B)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
1993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-4-5-8-5-4-4-4-12-9-22-17-25-6-19-28-34-40-35-19-28-52-82-156-280-183-184-132-418-1,743-657-545
0000000031131000111124689854122941
0000000000000000000000000000000
0000000000-00-000000-0.01000.010.01-0.010-0.02-0.020.011.73-0.36-0.38
00110000000-92121051186123142463131486504704252
00000000001011110000000612121213191817
000000000000000000000000000012180
-4-5-6-3-4-3-3-10-4-21-17-30-5-14-26-24-32-32-23-18-45-67-126-258-144-184-136-42322-415-713
00000000-2-9-2-10-1-2-50-10-4-5-7-18-18-4-1-1-54-57-93-53
0000000-13-5-9-1-10-6624292-2118-3216-129-2128362838-377100-93-58
0000000-12-30000-6526353-1919-2722-122-346403040-3231570-5
0000000000000000000000000000000
0000000191010031-1000-15000000324000-96-12781-352
00000.01000.020.0100.040.010.020.0600.020.060.020.010.050.130.110.2100.060.10.11.120.590.250.36
55112514371513442220560174223115313110920827964102989844613254
551100000000-1500000000000-48000-390-5-3
0000000000000000000000000000000
004-21-20145-1724-914-24-22211-3063102-876048-43-530566879-179-765
-5.1-5.6-6.3-3.4-4.2-3.8-3.7-10.8-6.9-30.8-19.5-31.7-5.9-16.2-28.7-30-33.5-34.5-24.2-22.5-51.2-74.3-144.4-277-148.7-186.2-138.5-97.1265.4-508.9-767.74
0000000000000000000000000000000

Novavax stock margins

The Novavax margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Novavax. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Novavax.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Novavax's sales revenue. A higher gross margin percentage indicates that the Novavax retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Novavax's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Novavax's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Novavax's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Novavax. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Novavax's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Novavax Margin History

Novavax Gross marginNovavax Profit marginNovavax EBIT marginNovavax Profit margin
2030e70.43 %0 %18.19 %
2029e70.43 %34.55 %16.95 %
2028e70.43 %37.4 %27.13 %
2027e70.43 %1.19 %-17.71 %
2026e70.43 %17.99 %5.81 %
2025e70.43 %45.61 %34.89 %
202470.43 %-34 %-27.49 %
202365.1 %-56.14 %-55.41 %
202254.45 %-32.53 %-33.2 %
202170.43 %-147.13 %-152.12 %
202070.43 %-87.62 %-87.95 %
201970.43 %-693.05 %-709.63 %
201870.43 %-507 %-538.48 %
201770.43 %-550.32 %-589.1 %
201670.43 %-1,747.4 %-1,818.18 %
201570.43 %-433.06 %-432.23 %
201451.14 %-272.64 %-270.03 %
201360.77 %-250.72 %-248.8 %
201233.48 %-134.39 %-128.96 %
201152.38 %-146.94 %-131.97 %
2010100 %-12,833.33 %-11,900 %
200970.43 %-12,466.67 %-13,433.33 %
200870.43 %-3,127.27 %-3,136.36 %
200770.43 %-2,020 %-2,320 %
200688.24 %-1,241.18 %-1,358.82 %
200592.45 %-286.79 %-211.32 %

Novavax Stock Sales Revenue, EBIT, Earnings per Share

The Novavax earnings per share therefore indicates how much revenue Novavax has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Novavax earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Novavax's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Novavax’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Novavax's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Novavax Revenue, EBIT and net profit per share

DateNovavax Sales per ShareNovavax EBIT per shareNovavax Earnings per Share
2030e3.03 undefined0 undefined0.55 undefined
2029e2.65 undefined0 undefined0.45 undefined
2028e2.67 undefined0 undefined0.72 undefined
2027e1.82 undefined0 undefined-0.32 undefined
2026e3.34 undefined0 undefined0.19 undefined
2025e6.96 undefined0 undefined2.43 undefined
20244.48 undefined-1.52 undefined-1.23 undefined
20239.76 undefined-5.48 undefined-5.41 undefined
202225.34 undefined-8.24 undefined-8.41 undefined
202115.41 undefined-22.67 undefined-23.44 undefined
20208.26 undefined-7.23 undefined-7.26 undefined
20190.78 undefined-5.38 undefined-5.51 undefined
20181.85 undefined-9.4 undefined-9.98 undefined
20172.14 undefined-11.76 undefined-12.59 undefined
20161.14 undefined-19.93 undefined-20.74 undefined
20152.77 undefined-12 undefined-11.98 undefined
20142.72 undefined-7.41 undefined-7.34 undefined
20132.46 undefined-6.16 undefined-6.12 undefined
20123.35 undefined-4.5 undefined-4.32 undefined
20112.58 undefined-3.79 undefined-3.4 undefined
20100.06 undefined-7.4 undefined-6.87 undefined
20090.07 undefined-8.7 undefined-9.37 undefined
20080.32 undefined-10.12 undefined-10.15 undefined
20070.48 undefined-9.77 undefined-11.23 undefined
20060.59 undefined-7.28 undefined-7.97 undefined
20052.52 undefined-7.24 undefined-5.33 undefined

Novavax business model

Novavax Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative vaccines and products for the treatment of infectious diseases. The company was founded in 1987 in Maryland, USA, and has since relocated its headquarters to Gaithersburg, Maryland. Novavax is a pioneer in vaccine technology. The company's business model is based on the development of vaccines for diseases such as malaria, Zika, RSV, and COVID-19. Novavax uses the latest technology and methods to ensure the highest efficacy and safety of its vaccines. By licensing its own technologies and licenses, the company has significantly increased its reach and effectiveness, establishing successful partnerships with institutions such as the Bill and Melinda Gates Foundation and the US Department of Defense. The different divisions of the company are focused on the development of vaccines and antiviral therapies. Novavax is involved in clinical development and has a portfolio of vaccine candidates targeting T-cells and antibodies. Currently, Novavax is conducting studies in the field of Respiratory Syncytial Virus (RSV) vaccination. The RSV program is Novavax's oldest program, launched in 1995, and the company has developed several vaccine candidates. A recent Phase III trial of an RSV vaccine candidate for the prevention of RSV infections in pregnant women did not meet its goals. However, it is a key position in vaccine development, allowing the company to focus on the development of vaccines against other infectious diseases. Novavax also has an ongoing research program focused on developing a COVID-19 vaccine candidate based on a protein called Nanoparticle Spike Protein (NVX-CoV2373) expressed in insect cells. A major advantage of this program is that it allows for faster manufacture of millions of doses with high throughput and has consistently shown positive results in clinical studies. The company has also developed a revolutionary technology called Matrix-M, which is used in its vaccines to enhance the immune response and activity against the vaccine. It is an adjuvant technology that stimulates the body to respond to a vaccine and achieve higher immunity against the pathogen. Novavax has a number of vaccine candidates in clinical development, including vaccines against malaria, influenza, and human papillomavirus (HPV), as well as an antiviral therapy for the treatment of RSV. These programs are still in the early stages of development, but the company is confident that it will be successful in the future. Overall, Novavax is a company specializing in the development of innovative vaccines and antiviral therapies for the treatment of infectious diseases. With a focus on safety, efficacy, and innovation, the company has achieved a leading position in vaccine technology and has become a key player in the global health landscape. Answer: Novavax is a biopharmaceutical company that specializes in developing and marketing innovative vaccines and products for treating infectious diseases. It was founded in 1987 in Maryland, USA, and focuses on developing vaccines against diseases like malaria, Zika, RSV, and COVID-19. The company uses advanced technology and methods to ensure the effectiveness and safety of its vaccines. It has partnerships with institutions like the Bill and Melinda Gates Foundation and the US Department of Defense. Novavax is also involved in clinical development and has a portfolio of vaccine candidates targeting T-cells and antibodies. Its oldest program is focused on developing an RSV vaccine, and it also has a program focused on developing a COVID-19 vaccine. Novavax has developed a technology called Matrix-M, which enhances the immune response to vaccines. It also has vaccine candidates in development for malaria, influenza, and HPV, as well as an antiviral therapy for RSV. Overall, Novavax is a leading company in vaccine technology and aims to develop effective and innovative vaccines and antiviral therapies for infectious diseases. Novavax is one of the most popular companies on Eulerpool.com.

Novavax SWOT Analysis

Strengths

Novavax Inc has a diverse portfolio of vaccine candidates covering various diseases.

Their technology platform, recombinant nanoparticle, has shown promising results in preclinical and clinical trials.

The company has a strong research and development team with extensive expertise in vaccine development.

Novavax has established collaborations with global organizations, enhancing their reach and market presence.

Weaknesses

Novavax Inc has experienced delays in their product development timelines, which may impact their competitive advantage.

The company is heavily reliant on successful clinical trials and regulatory approvals for their vaccine candidates.

Novavax faces potential competition from other vaccine developers in the market.

Opportunities

The growing demand for vaccines, especially during global health crises, presents significant opportunities for Novavax.

Expanding their vaccine portfolio to cover emerging diseases could open new markets and revenue streams for the company.

Collaborating with governments and international organizations to address global health challenges can lead to partnerships and funding opportunities.

Threats

The unpredictable nature of disease outbreaks and pandemics could impact Novavax's ability to timely develop and distribute vaccines.

Competition in the vaccine industry is intense, with established players and new entrants continuously emerging.

Regulatory challenges and potential adverse events related to vaccines may hinder market acceptance and revenue generation.

Novavax Revenue by Segment

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Novavax Revenue by Segment

Segmente2022202120192018
Product sales1.55 B USD---
Grants382.92 M USD948.71 M USD--
Royalties and other43.99 M USD197.58 M USD--

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Novavax Revenue by Segment

Segmente2022202120192018
Sales-Based Royalties9 M USD178.6 M USD--

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Novavax Revenue by Segment

Segmente2022202120192018
Grant--11.16 M USD34.29 M USD
Government Contract--7.5 M USD-
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Novavax Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Novavax historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Novavax shares outstanding

The number of shares was Novavax in 2024 — This indicates how many shares 152.19 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Novavax earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Novavax's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Novavax’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Novavax's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Novavax stock splits

In Novavax's history, there have been no stock splits.
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Novavax.

Novavax latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/20250.72 2.93  (306.89 %)2025 Q1
12/31/2024-0.52 -0.83  (-58.31 %)2024 Q4
9/30/2024-0.81 -0.76  (5.92 %)2024 Q3
6/30/20241.67 0.99  (-40.73 %)2024 Q2
3/31/2024-1.09 -1.05  (3.25 %)2024 Q1
12/31/2023-0.46 -1.44  (-214.89 %)2023 Q4
9/30/2023-1.87 -1.26  (32.56 %)2023 Q3
6/30/2023-1.41 0.58  (141.01 %)2023 Q2
3/31/2023-3.53 -3.41  (3.43 %)2023 Q1
12/31/2022-0.94 -2.28  (-142.97 %)2022 Q4
1
2
3
4
5
...
10

Eulerpool ESG Scorecard© for the Novavax stock

Eulerpool World ESG Rating (EESG©)

48/ 100

🌱 Environment

48

👫 Social

74

🏛️ Governance

21

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Novavax shareholders

%
Name
Stocks
Change
Date
10.27735 % The Vanguard Group, Inc.15,641,092-57,5123/31/2025
7.59594 % BlackRock Institutional Trust Company, N.A.11,560,258-518,9033/31/2025
7.31444 % Shah Capital Management, Inc.11,131,846-17,0003/31/2025
4.62524 % State Street Global Advisors (US)7,039,158-662,2083/31/2025
4.52098 % Sanofi SA6,880,48103/31/2025
4.27098 % SK Bioscience Co., Ltd.6,500,00005/10/2024
2.52118 % Coatue Management, L.L.C.3,836,9863,836,9863/31/2025
2.47323 % Geode Capital Management, L.L.C.3,764,008106,3133/31/2025
2.14266 % D. E. Shaw & Co., L.P.3,260,908-2,529,3463/31/2025
1.66164 % Park West Asset Management LLC2,528,8572,528,8573/31/2025
1
2
3
4
5
...
10

Novavax Executives and Management Board

Mr. John Jacobs

(57)
Novavax President, Chief Executive Officer, Director (since 2023)
Compensation 7.3 M

Mr. John Trizzino

(64)
Novavax President, Chief Operating Officer
Compensation 1.88 M

Mr. Mark Casey

(59)
Novavax Executive Vice President, Chief Legal Officer, Company Secretary
Compensation 1.53 M

Mr. James Kelly

(58)
Novavax Chief Financial Officer, Executive Vice President, Treasurer
Compensation 1.5 M

Mr. Richard Rodgers

(57)
Novavax Independent Director
Compensation 191,783
1
2
3

Most common questions regarding Novavax

What values and corporate philosophy does Novavax represent?

Novavax Inc represents values of innovation, dedication, and collaboration in the biotechnology industry. With a corporate philosophy focused on developing novel vaccines to prevent infectious diseases, Novavax aims to improve global health outcomes. Their commitment to scientific excellence and rigorous research enables them to address evolving public health challenges. Novavax Inc strives to make a positive impact by developing safe and effective vaccines, leveraging their technological expertise and diverse partnerships. Through their tireless efforts, Novavax Inc aims to provide innovative solutions to protect communities worldwide, solidifying their position as a leading biotech company.

In which countries and regions is Novavax primarily present?

Novavax Inc is primarily present in multiple countries and regions. The company has a global presence and operates in various key markets. Some of the primary countries and regions where Novavax Inc is actively engaged include the United States, United Kingdom, Canada, Europe, and Australia. With its innovative and cutting-edge approach to vaccine development, Novavax Inc aims to offer its healthcare solutions to a wide range of international markets. The company's commitment to expanding its presence ensures that its groundbreaking medical technologies reach people across different countries and regions, fostering better health outcomes worldwide.

What significant milestones has the company Novavax achieved?

Novavax Inc has achieved several significant milestones. One of the key achievements includes the development of a proprietary recombinant nanoparticle vaccine technology platform called Matrix-M. This innovative platform has facilitated the creation of multiple vaccine candidates targeting viral diseases. Novavax Inc has also successfully conducted clinical trials and achieved positive results for various vaccines, including those targeting respiratory syncytial virus (RSV) and influenza. Furthermore, the company has collaborated with renowned organizations, such as the Coalition for Epidemic Preparedness Innovations (CEPI) and the Bill & Melinda Gates Foundation, demonstrating its recognition and partnerships within the industry.

What is the history and background of the company Novavax?

Novavax Inc. is a leading biotechnology company focused on the development of innovative vaccines. Founded in 1987, Novavax has a rich history of scientific excellence and groundbreaking research. The company is committed to addressing urgent global health challenges and has made significant advancements in the field of vaccine development. Novavax has pioneered the use of recombinant nanoparticle vaccine technology and has successfully produced vaccine candidates for a range of infectious diseases, including respiratory syncytial virus (RSV), influenza, and COVID-19. With its strong research capabilities and dedicated team, Novavax continues to strive for transformative solutions in public health through its pioneering vaccine technologies.

Who are the main competitors of Novavax in the market?

The main competitors of Novavax Inc in the market are companies like Moderna, Pfizer, and Johnson & Johnson.

In which industries is Novavax primarily active?

Novavax Inc is primarily active within the biotechnology and pharmaceutical industries.

What is the business model of Novavax?

The business model of Novavax Inc revolves around developing innovative vaccines to address infectious diseases. Novavax is a biotechnology company that focuses on the discovery, development, and commercialization of vaccines for various viral infections. With a particular focus on respiratory diseases, including influenza and respiratory syncytial virus (RSV), Novavax utilizes cutting-edge technologies to create vaccines that stimulate protective immune responses. The company's approach includes the use of recombinant nanoparticle vaccine technology, which enables the production of vaccine antigens that closely mimic targeted viruses. Novavax strives to provide advanced vaccine solutions to combat prevalent and emerging infectious diseases worldwide.

What is the P/E ratio of Novavax 2025?

The P/E ratio cannot be calculated for Novavax at the moment.

What is the P/S ratio of Novavax 2025?

The P/S cannot be calculated for Novavax currently.

What is the Quality Investing of Novavax?

The Quality Investing for Novavax is 6/10.

What is the revenue of Novavax 2025?

The expected Novavax revenue is 1.06 B USD.

How high is the profit of Novavax 2025?

The expected Novavax profit is 369.79 M USD.

What is the business model of Novavax

Novavax Inc. is a biopharmaceutical company specializing in the development of innovative vaccines and treatments for a variety of infectious diseases. The company was founded in 1987 and is headquartered in Gaithersburg, Maryland, USA.

What is the Novavax dividend?

Novavax pays a dividend of 0 USD distributed over payouts per year.

How often does Novavax pay dividends?

The dividend cannot currently be calculated for Novavax or the company does not pay out a dividend.

What is the Novavax ISIN?

The ISIN of Novavax is US6700024010.

What is the Novavax WKN?

The WKN of Novavax is A2PKMZ.

What is the Novavax ticker?

The ticker of Novavax is NVAX.

How much dividend does Novavax pay?

Over the past 12 months, Novavax paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Novavax is expected to pay a dividend of 0 USD.

What is the dividend yield of Novavax?

The current dividend yield of Novavax is .

When does Novavax pay dividends?

Novavax pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Novavax?

Novavax paid dividends every year for the past 0 years.

What is the dividend of Novavax?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Novavax located?

Novavax is assigned to the 'Health' sector.

Wann musste ich die Aktien von Novavax kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Novavax from 7/16/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/16/2025.

When did Novavax pay the last dividend?

The last dividend was paid out on 7/16/2025.

What was the dividend of Novavax in the year 2024?

In the year 2024, Novavax distributed 0 USD as dividends.

In which currency does Novavax pay out the dividend?

The dividends of Novavax are distributed in USD.

All fundamentals about Novavax

Our stock analysis for Novavax Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Novavax Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.